Bexarotene Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 75 mg
Reference Brands: Targretin (USA/EU)
Category:
Oncology Cancer Care
Bexarotene is a retinoid X receptor (RXR) agonist used in the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer. It works by regulating the expression of genes that control cell growth, differentiation, and apoptosis (cell death), thereby slowing or stopping the growth of cancer cells.
Bexarotene is available in Capsules
and strengths such as 75 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Bexarotene is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Bexarotene can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Bexarotene is an antineoplastic (anti-cancer) medicine sold under the brand name Targretin and is primarily used in the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin lymphoma that mainly affects the skin. It belongs to the third generation of retinoids and works by selectively activating retinoid X receptors, which regulate gene expression involved in cell growth, differentiation, and programmed cell death. Through this targeted action, bexarotene helps slow the proliferation of malignant T-cells and reduces skin lesion severity.
Bexarotene is available in both systemic and topical forms. The oral form is indicated for patients with CTCL whose disease has not responded to at least one prior systemic therapy. The topical form is used for the treatment of skin lesions in patients with refractory or persistent CTCL, or in those who cannot tolerate other available treatments. Therapy with bexarotene requires medical supervision and regular monitoring, as it can affect lipid levels, thyroid function, and liver parameters. It is an important option in advanced or treatment-resistant CTCL management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing